This New England Startup Is Developing An Analyzer That Will Detect Coronavirus
The person who headed up developing the Anthrax detection machine for the government in 2001 now has his own public diagnostic company utilizing the technology developed then.LexaGene is the public company (TSX.V: LXG OTCQB: Symbol LXXGF) with market cap of $ 59 million.
LexaGene is a biotechnology company developing genetic analyzers for pathogen detection and other molecular markers.
Top Markets Targeted 1) Veterinary Diagnostics-(Market Size $5.4 Billion USD)-ONE Hour turnaround 2) Food Safety –e-Coli-Cannabis-Hemp-etc 48 million illnesses in US (Market Size $ 24 Billion) 3) Clinical Diagnostics ($12.9 Billion USD)-includes pandemics Other Water Safety/ Genotyping/Cruise Ships/Border Crossing etc.
Video testimonial from the veterinary team can be viewed in the following video. The following is a Video of the Beta Prototype TEST at Massachusetts Veterinary Referral Hospital (4 min):
Market Data 
Markets 
AI
